Report Highlights
The global central nervous system (CNS) biomarkers market should reach $9.5 billion by 2027 from $5.7 billion in 2022 at a compound annual growth rate (CAGR) of 10.8% for the forecast period of 2022 to 2027.
Report Includes
- 43 tables
- An overview of the global market and technologies for central nervous system (CNS) biomarkers
- Estimation of the market size and analyses of market trends, with data from 2019 to 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
- Explanation of market drivers, restraints and other forces impacting the global market
- Description of technologies such as genomics, proteomics, and imaging, and assessments of their advantages and disadvantages.
- Discussion of CNS disease segments, prevalence, and gaps in treatment for Alzheimer’s disease, depression, Parkinson’s disease, multiple sclerosis, and others
- Coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
- Comprehensive company profiles of major players of the industry, including Abbott, Bio-Rad Laboratories Inc., Eisai Co. Ltd., Merck and Thermo Fisher Scientific Inc.
Report Scope
This study provides a comprehensive analysis of CNS biomarkers on a global basis. Its aim is to provide a range of information, from detailed product analyses within disease subsegments to overall industry trends, in order to quantify and qualify the global CNS biomarkers market.
Current and projected product forecasts during the forecast period (2022 to 2027) are discussed. New products approved in 2021 and 2022 by the U.S. Food and Drug Administration (FDA), and those products expected to be approved within the forecast period are discussed. Market figures for 2022 are estimated, except where actual results have been reported.
Included in this report are forecasts by biomarker type, technology type, disease, application, and region from 2022 through 2027. The report also includes analysis of leading and emerging competitors in the current worldwide CNS biomarkers market. Profiles of manufacturers of leading products as well as biotechnology companies with novel products in development are analyzed to define the specific product strategies employed. This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment. The competitive environment is examined with a special focus on how new products and technologies are influencing the current standard of care.
Report Synopsis
| Report Metrics | Details | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Base year considered | 2021 | ||||||||||||||||||
| Forecast period considered | 2022-2027 | ||||||||||||||||||
| Base year market size | $5.2 billion | ||||||||||||||||||
| Market size forecast | $9.5 billion | ||||||||||||||||||
| Growth rate | CAGR of 10.8% | ||||||||||||||||||
| Units considered | $ Millions | ||||||||||||||||||
| Segments covered | Disease, Application, Technology, Biomarker Type, | ||||||||||||||||||
| Regions covered | North America, Europe, Asia-Pacific, and ROW | ||||||||||||||||||
| Countries covered | United States, Canada, Germany, France, United Kingdom, Italy, Rest of Europe, China, India, Japan, Rest of Asia-Pacific, Latin America, Middle East and Africa | ||||||||||||||||||
| Key Market Drivers |
|
||||||||||||||||||
| Companies studied |
|
Frequently Asked Questions (FAQs)
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
Report Highlights
The global CNS biomarker market is projected to reach $5.1 billion by 2020 from $3.1 billion in 2015, at a compound annual growth rate (CAGR) of 10.4%.
Report Includes
- An overview of the global market for central nervous system (CNS) biomarkers, which are measurable and quantifiable biological indicators that can be used to diagnose or predict disease, monitor disease progression, and predict treatment response.
- Analyses of global market trends, with data from 2014 and 2015, and projections of compound annual growth rates (CAGRs) through 2020.
- Evaluation of technologies such as genomics, proteomics, and imaging, and assessments of their advantages and disadvantages.
- Discussion of CNS disease segments, prevalence, and gaps in treatment for Alzheimer’s disease, depression, Parkinson’s disease, multiple sclerosis, and others.
- Patent analyses.
- Profiles of major players in the field.
Report Highlights
The global CNS biomarker market was estimated at $1.7 billion in 2011 and nearly $2 billion in 2012. The market is projected to reach $5.1 billion by the end of the forecast period of 2012 to 2017, representing a compound annual growth rate (CAGR) of 20.7%.
Report Includes
- An overview of the global market for central nervous system (CNS) biomarkers, which are measurable and quantifiable biological indicators that can be used to diagnose or predict disease, monitor disease progression, and predict treatment response.
- Analyses of global market trends, with data from 2010 through 2012, and projections of compound annual growth rates (CAGRs) through 2017.
- Evaluations of technologies such as genomics, proteomics, and imaging, and assessments of their advantages and disadvantages.
- Discussion of CNS disease segments, prevalence, and gaps in treatment for Alzheimer’s disease, depression, Parkinson’s disease, multiple sclerosis, and others.
- Patent analyses.
- Comprehensive company profiles of major players.
Report Highlights
-
The global CNS biomarker market was estimated at $1.3 billion in 2009 and is expected to reach close to $3.2 billion by 2015, with a compound annual growth rate (CAGR) of 17.1% from 2010 to 2015.
-
The CNS molecular diagnostic market will see the largest growth, with a compound annual growth rate (CAGR) of 172.3% from 2010 to 2015 due to the number of diagnostic tests that are in the pipeline. This sector is valued at $2 million in 2010 and is expected to be worth $302 million in 2015.
-
The growth rate for the CNS biomarker market for drug development will increase as more validated biomarkers become available for patient segmentation and assessment of efficacy for clinical trials. This sector is worth an estimated $162 million in 2010 and is expected to reach $355 million in 2015, a 17% compound annual growth rate (CAGR).
Related Reports
Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders
The global progressive ataxia and weakness disorders market reached $32.0 billion in 2022, should reach $35.1 billion by 2023 and $57.2 billion by 2028 with a compound annual growth rate (CAGR) of 10.2% during the forecast period of 2023-2028.
Companion Diagnostics: Technologies and Markets
The global market for companion diagnostics (CDx) is estimated to increase from $6.4 billion in 2022 to reach $13.0 billion by 2027, at a compound annual growth rate (CAGR) of 15.3% from 2022 through 2027.
Emerging Tools for Alzheimer's Disease
The goal is to provide an analysis of the emerging tools for the early detection of Alzheimer’s disease (AD) and their growth potential and future opportunities in the market. Because currently available tools are invasive and very expensive, there is a significant unmet need for non-invasive, cost-effective and early-detection tools. The study’s main objective is to present a comprehensive analysis of the emerging tools, including those that are approved and those in development, and predict their impact on the market.
Cardiac Biomarkers: Technologies and Global Markets
The global market for cardiac biomarkers is estimated to increase from $13.4 billion in 2022 to reach $23.8 billion by 2027, at a compound annual growth rate (CAGR) of 12.2% from 2022 through 2027.
Recent Reports
Exosome Diagnostics, Therapeutics and Research Tools: Global Markets
The global market for exosome diagnostics, therapeutics and research tools is estimated to increase from $227.5 million in 2023 to reach $1.3 billion by 2028, at a compound annual growth rate (CAGR) of 42.2% from 2023 through 2028.
Peptide Synthesis: Global Markets
The global market for peptide synthesis is expected to grow from $90.1 billion in 2023 and projected to reach $157.5 billion by the end of 2028, at a compound annual growth rate (CAGR) of 11.8% during the forecast period of 2023 to 2028.
Oligonucleotides: Global Markets
The global market for oligonucleotides is expected to grow from $7.0 billion in 2023 and projected to reach $11.7 billion by the end of 2028, at a compound annual growth rate (CAGR) of 11.0% during the forecast period of 2023 to 2028.
Global Market for Cell and Gene Therapy
The global market for cell and gene therapy is expected to grow from $7.2 billion in 2023 and projected to reach $23.3 billion by the end of 2028, at a compound annual growth rate (CAGR) of 26.4% during the forecast period of 2023 to 2028.
Viral Vector and Plasmid DNA: Technologies and Global Markets
The global market for viral vector and plasmid DNA technologies is expected to grow from $2.9 billion in 2023 to $7.1 billion by the end of 2028, at a compound annual growth rate (CAGR) of 19.7% from 2023 through 2028.
Top Trending Reports
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for cell and gene therapy tools and reagents is estimated to grow from $8.3 billion in 2022 to $13.7 billion in 2027, with a compound annual growth rate (CAGR) of 10.6% for the period of 2022-2027.
Flame Retardant Chemicals: Technologies and Global Markets
The global consumption of flame retardant chemicals is estimated to grow from 6.0 billion pounds in 2022 to 7.5 billion pounds in 2027, at a compound annual growth rate (CAGR) of 4.4% for the period of 2022-2027.
Biorefinery Products: Global Markets
The global market for biorefinery products is estimated to increase from $624.7 billion in 2022 to $920.0 billion by 2027, at a compound annual growth rate (CAGR) of 8.0% from 2022 through 2027.
Electric Vehicle Charging: Infrastructure and Global Markets
The global market for wired electric vehicle charging infrastructure is estimated to grow from $24.1 billion in 2022 to $81.1 billion in 2027, at a compound annual growth rate (CAGR) of 27.4% for the period of 2022-2027.
Digital Pathology: Technologies and Global Markets
The global digital pathology market is estimated to increase from $5.9 billion in 2022 to reach $10.7 billion by 2027, at a compound annual growth rate (CAGR) of 12.5% from 2022 through 2027.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More